The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association between tumor burden and response to immunotherapy in patients with metastatic renal cell carcinoma.
 
Hesham Abdallah Yasin
No Relationships to Disclose
 
Yu-Wei Chen
Stock and Other Ownership Interests - Biogen (I)
Consulting or Advisory Role - Deloitte
 
Matthew D Tucker
No Relationships to Disclose
 
Katy Beckermann
Consulting or Advisory Role - Aravive; Bristol-Myers Squibb; Exelixis; Seagen
Research Funding - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Kerry Schaffer
Consulting or Advisory Role - Janssen Biotech
Research Funding - Tempus (Inst)
 
Nancy B. Davis
Consulting or Advisory Role - Janssen Biotech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Incyte (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Seattle Genetics/Astellas (Inst)
 
Renee McAlister
Consulting or Advisory Role - Immunocore; Myovant Sciences; Sanofi/Regeneron
 
Deborah Wallace
No Relationships to Disclose
 
Elizabeth Kaiser
No Relationships to Disclose
 
Brian I. Rini
Leadership - MJH Life Sciences
Stock and Other Ownership Interests - PTC Therapeutics
Consulting or Advisory Role - 3D Medicines; Aravive; Arrowhead Pharmaceuticals; AVEO; Bristol-Myers Squibb; Corvus Pharmaceuticals; Eisai; GlaxoSmithKline; Merck; Pfizer; Shionogi; Surface Oncology; synthorx
Research Funding - Aravive (Inst); Arrowhead Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Dragonfly Therapeutics (Inst); Exelixis (Inst); Immunomedics (Inst); Incyte (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); Surface Oncology (Inst); Taris (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Pfizer